|
Indications and Dosage
Intramuscular
Anaemia, Breast cancer in postmenopausal women, Catabolic disorders, Osteopetrosis Adult: 50 mg every 2-3 wk. Oral Vascular manifestations of Behcet's syndrome Adult: 10 mg daily. Oral Hereditary angioedema Adult: Initially, 2.5-10 mg daily, reduced according to response. Maintenance: 2 mg daily or on alternate days or 2.5 mg 3 times wkly.
Child: <6 yr: 1 mg daily; 6-12 yr: Up to 2 mg daily. |
|
Contraindications
Pregnancy and lactation; carcinoma of prostate or breast in men, hypercalcaemia, hypercalciuria, porphyria, severe hepatic impairment.
|
|
Special Precautions
Patients with cardiac, renal or hepatic disease, epilepsy or DM. Children, elderly. Monitor liver function, haematocrit and haemoglobin concentrations. Not recommended for treatment of hereditary angioedema in premenopausal women.
|
|
Adverse Reactions
Peliosis hepatis, premature epiphyseal closure, cholestatic jaundice, virilism, impotence, priapism, testicular atrophy, gynaecomastia, prostatic hyperplasia, decreased libido, hirsutism, menstrual irregularities; oedema, acne.
Potentially Fatal: Hepatic necrosis, hepatocellular carcinoma. |
|
Drug Interactions
Enhances activity of insulin, sulfonylureas, levothyroxine and anticoagulants e.g. warfarin. May cause resistance to the effects of neuromuscular blockers.
|
|
Lab Interference
May interfere with laboratory tests for glucose tolerance and thyroid function.
|
|
Action
Description: Stanozolol is a structural analogue of testosterone which increases collagen production and decreases the anti-anabolic action of cortisone. It is also reported to reduce fibrin deposition. It corrects the formation of kinin or kinin-like factors which may be associated with oedema and swelling seen in hereditary angioedema.
Pharmacokinetics: Metabolism: Hepatic. Excretion: Urine (90%), faeces (6%). |
|
MIMS Class
|
Sign Out
